Core Viewpoint - Silver诺医药's new veterinary drug clinical trial application for the treatment of pet diabetes has been accepted by the Ministry of Agriculture, leading to a significant stock price increase of up to 20%, reaching HKD 31 [1] Group 1: Clinical Trial and Product Development - The core product, Isupatide α, is aimed at treating diabetes in pets, with the first phase of clinical trials expected to commence in the first quarter of this year [1] - The board believes that developing diabetes medication for pets has vast potential due to increasing consumer willingness to spend on extending their pets' lifespans [1] Group 2: Strategic Business Development - The board views this research and development as aligned with the company's long-term business strategy, establishing a solid foundation for future entry into the pet pharmaceuticals market [1]
银诺医药一度飙升20%，新兽药临床试验申请获受理
Ge Long Hui·2026-02-05 07:12